第 1 到 53 筆結果,共 53 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2023 | Whole exome sequencing and MicroRNA profiling of lung adenocarcinoma identified risk prediction features for tumors at stage I and its substages | Ho, Hao; SUNG-LIANG YU ; Chen, Hsuan-Yu; Yuan, Shin-Sheng; KANG-YI SU ; Hsu, Yi-Chiung; Hsu, Chung-Ping; Chuang, Cheng-Yen; Chang, Ya-Hsuan; Li, Yu-Cheng; Cheng, Chiou-Ling; Chang, Gee-Chen; PAN-CHYR YANG ; Li, Ker-Chau | Lung cancer (Amsterdam, Netherlands) | 1 | 0 | |
2 | 2023 | Senomorphic effect of diphenyleneiodonium through AMPK/MFF/DRP1 mediated mitochondrial fission | Liao, Keng-Mao; Chen, Chih-Jung; Luo, Wei-Jia; Hsu, Chen-Wei; SUNG-LIANG YU ; PAN-CHYR YANG ; KANG-YI SU | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 1 | 1 | |
3 | 2023 | LCRMP-1 is required for spermatogenesis and stabilises spermatid F-actin organization via the PI3K-Akt pathway | Chang, Jung-Hsuan; Chou, Chia-Hua; JUI-CHING WU ; Liao, Keng-Mao; Luo, Wei-Jia; Hsu, Wei-Lun; Chen, Xuan-Ren; SUNG-LIANG YU ; SZU-HUA PAN ; PAN-CHYR YANG ; KANG-YI SU | Communications biology | 0 | 0 | |
4 | 2022 | Tissue Proteogenomic Landscape Reveals the Role of Uncharacterized SEL1L3 in Progression and Immunotherapy Response in Lung Adenocarcinoma | Chi-ya Shen; Chang, Wen-Hsin; Chen, Yi-Ju; Weng, Chia-Wei; Regmi, Prabha; Kier, Mickiela K K; KANG-YI SU ; Chang, Gee-Chen; JIN-SHING CHEN ; Chen, Yu-Ju; SUNG-LIANG YU | Journal of proteome research | 4 | 0 | |
5 | 2022 | Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Targeted oncology | 0 | 0 | |
6 | 2022 | Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid | Liao, Pei-Ya; Ou, Wei-Fan; KANG-YI SU ; Sun, Ming-Hsi; Huang, Chih-Mei; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; SUNG-LIANG YU ; Huang, Yen-Hsiang; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chang, Gee-Chen | Cancers | 0 | 0 | |
7 | 2022 | The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Targeted oncology | 7 | 7 | |
8 | 2022 | The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Chin, Chun-Shih; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Cancer research and treatment | 9 | 6 | |
9 | 2022 | PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients | Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Huang, Yen-Hsiang; Chang, Gee-Chen | Scientific reports | 11 | 9 | |
10 | 2022 | HLJ1 amplifies endotoxin-induced sepsis severity by promoting IL-12 heterodimerization in macrophages | Luo, Wei-Jia; SUNG-LIANG YU ; Chang, Chia-Ching; Chien, Min-Hui; Chang, Ya-Ling; Liao, Keng-Mao; Lin, Pei-Chun; KUEI-PIN CHUNG ; YA-HUI CHUANG ; Chen, Jeremy J W; PAN-CHYR YANG ; KANG-YI SU | eLife | 7 | 3 | |
11 | 2022 | Novel Genetic Prognostic Signature for Lung Adenocarcinoma Identified by Differences in Gene Expression Profiles of Low- and High-Grade Histological Subtypes | Chang, Chia-Ching; MIN-SHU HSIEH ; MONG-WEI LIN ; Lee, Yi-Hsuan; Hsiao, Yi-Jing; KANG-YI SU ; Su, Te-Jen; SUNG-LIANG YU ; JIN-SHING CHEN | Biomolecules | 3 | 4 | |
12 | 2022 | Various impacts of driver mutations on the PD-L1 expression of NSCLC | Chu, Cheng-Hsiang; Huang, Yen-Hsiang; Lee, Po-Hsin; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chang, Gee-Chen | PloS one | 3 | 1 | |
13 | 2021 | Transthyretin as a Biomarker to Predict and Monitor Major Depressive Disorder Identified by Whole-Genome Transcriptomic Analysis in Mouse Models | SUNG-LIANG YU ; Chu, Selina Shih-Ting; Chien, Min-Hui; PO-HSIU KUO ; PAN-CHYR YANG ; KANG-YI SU | Biomedicines | 4 | 4 | |
14 | 2021 | Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M | Huang, Yen-Hsiang; Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Yang, Tsung-Ying; Chang, Gee-Chen | Scientific reports | 0 | 0 | |
15 | 2021 | The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M | Huang, Yen-Hsiang; Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Yang, Tsung-Ying; Chang, Gee-Chen | Scientific reports | 9 | 9 | |
16 | 2021 | Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan | SHANG-GIN WU ; WEI-YU LIAO ; KANG-YI SU ; SUNG-LIANG YU ; YEN-LIN HUANG ; CHONG-JEN YU ; CHIH-HSIN YANG ; JIN-YUAN SHIH | JTO Clinical and Research Reports | 16 | 0 | |
17 | 2021 | Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment | Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Zheng, Zhe-Rong; Yang, Tsung-Ying; Chen, Kun-Chieh; Huang, Yen-Hsiang; KANG-YI SU ; SUNG-LIANG YU ; Chang, Gee-Chen | Oncology | 9 | 9 | |
18 | 2020 | Copy Number Alterations of Depressed Colorectal Neoplasm Predict the Survival and Response to Oxaliplatin in Proximal Colon Cancer | LI-CHUN CHANG ; HAN-MO CHIU ; Ho, Bing-Ching; Chen, Min-Hsuan; Hsu, Yin-Chen; Chiu, Wei-Tzu; KANG-YI SU ; CHIA-TUNG SHUN ; JIN-TUNG LIANG ; SUNG-LIANG YU ; MING-SHIANG WU | Cancers | 6 | 5 | |
19 | 2020 | ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients | Chang, Gee-Chen; Yang, Tsung-Ying; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; Huang, Yen-Hsiang; KANG-YI SU ; SUNG-LIANG YU ; Tseng, Jeng-Sen | Scientific reports | 26 | 20 | |
20 | 2020 | Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression | Chen, Yi-Ju; Roumeliotis, Theodoros I; Chang, Ya-Hsuan; Chen, Ching-Tai; Han, Chia-Li; MIAO-HSIA LIN ; HUEI-WEN CHEN ; Chang, Gee-Chen; YIH-LEONG CHANG ; CHEN-TU WU ; MONG-WEI LIN ; MIN-SHU HSIEH ; Wang, Yu-Tai; Chen, Yet-Ran; Jonassen, Inge; Ghavidel, Fatemeh Zamanzad; Lin, Ze-Shiang; Lin, Kuen-Tyng; Chen, Ching-Wen; Sheu, Pei-Yuan; Hung, Chen-Ting; Huang, Ke-Chieh; Yang, Hao-Chin; Lin, Pei-Yi; Yen, Ta-Chi; Lin, Yi-Wei; Wang, Jen-Hung; Raghav, Lovely; Lin, Chien-Yu; Chen, Yan-Si; Wu, Pei-Shan; Lai, Chi-Ting; Weng, Shao-Hsing; KANG-YI SU ; Chang, Wei-Hung; Tsai, Pang-Yan; Robles, Ana I; Rodriguez, Henry; Hsiao, Yi-Jing; Chang, Wen-Hsin; Sung, Ting-Yi; JIN-SHING CHEN ; SUNG-LIANG YU ; Choudhary, Jyoti S; Chen, Hsuan-Yu; PAN-CHYR YANG ; Chen, Yu-Ju | Cell | 163 | 134 | |
21 | 2019 | Perinatal polychlorinated biphenyls and polychlorinated dibenzofurans exposure are associated with DNA methylation changes lasting to early adulthood: Findings from Yucheng second generation | KANG-YI SU ; Li M.-C.; Lee N.-W.; Ho B.-C.; Cheng C.-L.; Chuang Y.-C.; SUNG-LIANG YU ; Yue Leon Guo | Environmental Research | 18 | 15 | |
22 | 2019 | High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients | Hsu K.-H.; Huang Y.-H.; Tseng J.-S.; Chen K.-C.; Ku W.-H.; KANG-YI SU ; Chen J.J.W.; HUEI-WEN CHEN ; SUNG-LIANG YU ; Yang T.-Y.; Chang G.-C. | Lung Cancer | 64 | 52 | |
23 | 2018 | Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer | MONG-WEI LIN ; KANG-YI SU ; Su T.-J.; Chang C.-C.; Lin J.-W.; Lee Y.-H.; SUNG-LIANG YU ; JIN-SHING CHEN ; MIN-SHU HSIEH | Lung Cancer | 43 | 33 | |
24 | 2018 | FAM198B is associated with prolonged survival and inhibits metastasis in lung adenocarcinoma via blockage of ERK-Mediated MMP-1 expression | Hsu C.-Y.; Chang G.-C.; Chen Y.-J.; Hsu Y.-C.; Hsiao Y.-J.; KANG-YI SU ; Chen H.-Y.; Lin C.-Y.; JIN-SHING CHEN ; Chen Y.-J.; Hong Q.-S.; Ku W.-H.; Wu C.-Y.; Ho B.-C.; Chiang C.-C.; PAN-CHYR YANG ; SUNG-LIANG YU | Clinical Cancer Research | 20 | 20 | |
25 | 2018 | Intercalated treatment following rebiopsy is associated with a shorter progression-free survival of osimertinib treatment | Tseng J.-S.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Huang Y.-H.; KANG-YI SU ; SUNG-LIANG YU ; Chang G.-C. | Cancer Research and Treatment | 5 | 5 | |
26 | 2018 | Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma | KANG-YI SU ; Tseng J.-S.; Liao K.-M.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; PAN-CHYR YANG ; SUNG-LIANG YU ; Chang G.-C. | PLoS ONE | 18 | 13 | |
27 | 2018 | Characteristics and Predictive Value of PD-L1 Status in Real-World NonSmall Cell Lung Cancer Patients | Tseng J.-S.; Yang T.-Y.; Wu C.-Y.; Ku W.-H.; Chen K.-C.; Hsu K.-H.; Huang Y.-H.; KANG-YI SU ; SUNG-LIANG YU ; Chang G.-C. | Journal of Immunotherapy | 29 | 25 | |
28 | 2018 | The association of acquired T790M mutation with clinical characteristics after resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Chen, Kun-Chieh; Hsu, Chia-Hung; KANG-YI SU ; Chen, Jeremy J W; HUEI-WEN CHEN ; SUNG-LIANG YU ; Yang, Tsung-Ying; Chang, Gee-Chen | Cancer Research and Treatment | 47 | 45 | |
29 | 2017 | Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non–small cell lung cancer patients | SZU-HUA PAN ; KANG-YI SU ; Spiessens B.; Kusuma N.; Delahaye N.F.; Gruselle O.; Myo A.; de Creus A.; Louahed J.; Chang G.-C.; SUNG-LIANG YU ; PAN-CHYR YANG | Asia-Pacific Journal of Clinical Oncology | 14 | 14 | |
30 | 2017 | EGFR mutation, smoking, and gender in advanced lung adenocarcinoma | Tseng, Chien-Hua; CHUN-JU CHIANG ; Tseng, Jeng-Sen; Yang, Tsung-Ying; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; Wang, Chih-Liang; Chen, Chih-Yi; Yen, Sang-Hue; Tsai, Chun-Ming; Huang, Ming-Shyan; CHAO-CHI HO ; CHONG-JEN YU ; Tsai, Ying-Huang; JIN-SHING CHEN ; Chou, Teh-Ying; Tsai, Ming-Hsun; Chen, Hsuan-Yu; KANG-YI SU ; Chen, Jeremy J. W.; HUEI-WEN CHEN ; SUNG-LIANG YU ; Liu, Tsang-Wu; MONG-HSUN TSAI | Oncotarget | 54 | 41 | |
31 | 2017 | Rapid Sputum Multiplex Detection of the M. tuberculosis Complex (MTBC) and Resistance Mutations for Eight Antibiotics by Nucleotide MALDI-TOF MS | KANG-YI SU ; BO-SHIUN YAN ; HAO-CHIEH CHIU ; CHONG-JEN YU ; Chang S.-Y.; Jou R.; Liu J.-L.; PO-REN HSUEH ; SUNG-LIANG YU | Scientific Reports | 16 | 10 | |
32 | 2016 | SPANXA suppresses EMT by inhibiting c-JUN/SNAI2 signaling in lung adenocarcinoma | Hsiao Y.-J.; KANG-YI SU ; Hsu Y.-C.; Chang G.-C.; JIN-SHING CHEN ; Chen H.-Y.; Hong Q.-S.; Hsu S.-C.; Kang P.-H.; Hsu C.-Y.; Ho B.-C.; Yang T.-H.; Wang C.-Y.; Jou Y.-S.; PAN-CHYR YANG ; SUNG-LIANG YU | Oncotarget | 23 | 23 | |
33 | 2016 | Implementation and Quality Control of Lung Cancer EGFR Genetic Testing by MALDI-TOF Mass Spectrometry in Taiwan Clinical Practice | KANG-YI SU ; JAU-TSUEN KAO ; Ho B.-C.; Chen H.-Y.; Chang G.-C.; CHAO-CHI HO ; SUNG-LIANG YU | Scientific Reports | 13 | 11 | |
34 | 2016 | The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: Focus on rebiopsy timing and long-term existence of T790M | Tseng J.-S.; KANG-YI SU ; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Chen H.-Y.; Tsai C.-R.; SUNG-LIANG YU ; Chang G.-C. | Oncotarget | 24 | 23 | |
35 | 2016 | JAG1 is associated with poor survival through inducing metastasis in lung cancer | Chang W.-H.; Ho B.-C.; Hsiao Y.-J.; JIN-SHING CHEN ; Yeh C.-H.; Chen H.-Y.; Chang G.-C.; KANG-YI SU ; SUNG-LIANG YU | PLoS ONE | 30 | 29 | |
36 | 2016 | Molecular gene signature and prognosis of non-small cell lung cancer | Huang P.; Cheng C.-L.; Chang Y.-H.; Liu C.-H.; Hsu Y.-C.; JIN-SHING CHEN ; Chang G.-C.; Ho B.-C.; KANG-YI SU ; Chen H.-Y.; SUNG-LIANG YU | Oncotarget | 17 | 16 | |
37 | 2016 | HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms | Chen C.-H.; Chang W.-H.; KANG-YI SU ; Ku W.-H.; Chang G.-C.; Hong Q.-S.; Hsiao Y.-J.; Chen H.-C.; Chen H.-Y.; Wu R.; PAN-CHYR YANG ; Chen J.J.W.; SUNG-LIANG YU | Oncogene | 21 | 21 | |
38 | 2016 | Predilection of contralateral upper lung metastasis in upper lobe lung adenocarcinoma patients | Huang Y.-H.; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; KANG-YI SU ; Chen H.-Y.; Chang C.-S.; Chen J.J.W.; SUNG-LIANG YU ; HUEI-WEN CHEN ; Yang T.-Y.; Chang G.-C. | Journal of Thoracic Disease | 2 | 2 | |
39 | 2016 | Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients | Hsu K.-H.; Tseng J.-S.; Wang C.-L.; Yang T.-Y.; Tseng C.-H.; Chen H.-Y.; Chen K.-C.; Tsai C.-R.; Yang C.-T.; SUNG-LIANG YU ; KANG-YI SU ; CHONG-JEN YU ; CHAO-CHI HO ; Hsia T.-C.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; PAN-CHYR YANG ; Chen J.J.W.; Chang G.-C. | Oncotarget | 9 | 9 | |
40 | 2015 | Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan | Hsu K.-H.; CHAO-CHI HO ; Hsia T.-C.; Tseng J.-S.; KANG-YI SU ; Wu M.-F.; Chiu K.-L.; Yang T.-Y.; Chen K.-C.; Ooi H.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN ; WEI-YU LIAO ; JIN-YUAN SHIH ; SUNG-LIANG YU ; CHONG-JEN YU ; PAN-CHYR YANG ; Chang G.-C. | PLoS ONE | 98 | 92 | |
41 | 2015 | EGFR mutation and lobar location of lung adenocarcinoma | Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; CHAO-CHI HO ; Hsia T.-C.; KANG-YI SU ; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN ; WEI-YU LIAO ; JIN-YUAN SHIH ; SUNG-LIANG YU ; CHONG-JEN YU ; PAN-CHYR YANG ; Yang T.-Y.; Chang G.-C. | Carcinogenesis | 13 | 12 | |
42 | 2015 | R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability | Chen H.-Y.; SUNG-LIANG YU ; Ho B.-C.; KANG-YI SU ; Hsu Y.-C.; Chang C.-S.; Li Y.-C.; Yang S.-Y.; Hsu P.-Y.; Ho H.; Chang Y.-H.; Chen C.-Y.; Yang H.-I.; Hsu C.-P.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Hsia J.-Y.; Chuang C.-Y.; Yuan S.; Lee M.-H.; Liu C.-H.; Wu G.-I.; Hsiung C.A.; Chen Y.-M.; Wang C.-L.; Huang M.-S.; CHONG-JEN YU ; KUAN-YU CHEN ; Tsai Y.-H.; Su W.-C.; HUEI-WEN CHEN ; Chen J.J.W.; Chen C.-J.; Chang G.-C.; PAN-CHYR YANG ; Li K.-C. | Journal of Clinical Oncology | 76 | 71 | |
43 | 2015 | HOXA5 inhibits metastasis via regulating cytoskeletal remodelling and associates with prolonged survival in non-small-cell lung carcinoma | Wang C.-C.; KANG-YI SU ; Chen H.-Y.; Chang S.-Y.; Shen C.-F.; Hsieh C.-H.; Hong Q.-S.; Chiang C.-C.; Chang G.-C.; SUNG-LIANG YU ; Chen J.J.W. | PLoS ONE | 39 | 32 | |
44 | 2015 | Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma | Tseng, Jeng-Sen; Yang, Tsung-Ying; Tsai, Chi-Ren; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; Tsai, Meen-Hsin; SUNG-LIANG YU ; KANG-YI SU ; Chen, Jeremy J. W.; MONG-HSUN TSAI | Journal of Thoracic Oncology | 63 | 61 | |
45 | 2014 | Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma | Tseng, Jeng-Sen; Wang, Chih-Liang; Huang, Ming-Shyan; CHUNG-YU CHEN ; Chang, Cheng-Yu; Yang, Tsung-Ying; Tsai, Chi-Ren; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; Tsai, Meen-Hsin; SUNG-LIANG YU ; KANG-YI SU ; Wu, Chih-Wei; Yang, Cheng-Ta; Chen, Yuh-Min; MONG-HSUN TSAI | PLoS ONE | 12 | 12 | |
46 | 2014 | Shisa3 is associated with prolonged survival through promoting β-catenin degradation in lung cancer | Chen C.-C.; Chen H.-Y.; KANG-YI SU ; Hong Q.-S.; BO-SHIUN YAN ; Chen C.-H.; SZU-HUA PAN ; YIH-LEONG CHANG ; Wang C.-J.; Hung P.-F.; Yuan S.; Chang G.-C.; Chen J.J.W.; PAN-CHYR YANG ; YA-CHIEN YANG ; SUNG-LIANG YU | American Journal of Respiratory and Critical Care Medicine | 30 | 33 | |
47 | 2014 | Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma | Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; CHONG-JEN YU ; WEI-YU LIAO ; Tsai, Chi-Ren; Tsai, Meen-Hsin; SUNG-LIANG YU ; KANG-YI SU ; Chen, Jeremy Jw; Chen, Hsuan-Yu; MONG-HSUN TSAI | OncoTargets and Therapy | 15 | 14 | |
48 | 2012 | Rutin, a flavonoid that is a main component of Saussurea involucrata, attenuates the senescence effect in D-galactose aging mouse model | Yang Y.-C.; Lin H.-Y.; KANG-YI SU ; Chen C.-H.; Yu Y.-L.; Lin C.-C.; SUNG-LIANG YU ; Yan H.-Y.; Su K.-J.; Chen Y.-L.S. | Evidence-based Complementary and Alternative Medicine | 44 | 33 | |
49 | 2012 | Potential therapeutic role of Z-isochaihulactone in lung cancer through induction of apoptosis via notch signaling | Ou J.-P.; Lin H.-Y.; KANG-YI SU ; SUNG-LIANG YU ; Tseng I.-H.; Chen C.-J.; Hsu H.-C.; Chan D.-C.; Sophia Chen Y.-L. | Evidence-based Complementary and Alternative Medicine | 15 | 13 | |
50 | 2012 | Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer | KANG-YI SU ; Chen H.-Y.; Li K.-C.; Kuo M.-L.; CHIH-HSIN YANG ; Chan W.-K.; Ho B.-C.; Chang G.-C.; JIN-YUAN SHIH ; SUNG-LIANG YU ; PAN-CHYR YANG | Journal of Clinical Oncology | 464 | 428 | |
51 | 2011 | Enterovirus-induced miR-141 contributes to shutoff of host protein translation by targeting the translation initiation factor eIF4E | Ho B.-C.; SUNG-LIANG YU ; Chen J.J.W.; SUI-YUAN CHANG ; BO-SHIUN YAN ; Hong Q.-S.; Singh S.; CHUAN-LIANG KAO ; Chen H.-Y.; KANG-YI SU ; Li K.-C.; Cheng C.-L.; Cheng H.-W.; Lee J.-Y.; Lee C.-N.; PAN-CHYR YANG | Cell Host and Microbe | 135 | 127 | |
52 | 2011 | Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor | Chang T.-H.; Tsai M.-F.; KANG-YI SU ; SHANG-GIN WU ; Huang C.-P.; SUNG-LIANG YU ; Yu Y.-L.; Lan C.-C.; CHIH-HSIN YANG ; Lin S.-B.; Wu C.-P.; JIN-YUAN SHIH ; PAN-CHYR YANG | American Journal of Respiratory and Critical Care Medicine | 145 | 140 | |
53 | 2011 | Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations | Yuan S.; SUNG-LIANG YU ; Chen H.-Y.; Hsu Y.-C.; KANG-YI SU ; HUEI-WEN CHEN ; Chen C.-Y.; CHONG-JEN YU ; JIN-YUAN SHIH ; YIH-LEONG CHANG ; Cheng C.-L.; Hsu C.-P.; Hsia J.-Y.; Lin C.-Y.; Wu G.; Liu C.-H.; Wang C.-D.; Yang K.-C.; Chen Y.-W.; Lai Y.-L.; Hsu C.-C.; Lin T.-C.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Chen J.J.W.; Chang G.-C.; Li K.-C.; PAN-CHYR YANG | Journal of Clinical Oncology | 28 | 26 |